Adam L Green1,2, Jean M Mulcahy Levy3,4, Rajeev Vibhakar3,4, Molly Hemenway3,4, Jennifer Madden3,4, Nicholas Foreman3,4, Kathleen Dorris3,4. 1. Program in Neuro-Oncology, Center for Cancer and Blood Disorders, Children's Hospital Colorado, 12800 E. 19th Ave. RC1-N, Mail Stop 8302, Aurora, CO, 80045, USA. adam.green@ucdenver.edu. 2. Morgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, 12800 E. 19th Ave. RC1-N, Mail Stop 8302, Aurora, CO, 80045, USA. adam.green@ucdenver.edu. 3. Program in Neuro-Oncology, Center for Cancer and Blood Disorders, Children's Hospital Colorado, 12800 E. 19th Ave. RC1-N, Mail Stop 8302, Aurora, CO, 80045, USA. 4. Morgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, 12800 E. 19th Ave. RC1-N, Mail Stop 8302, Aurora, CO, 80045, USA.
Abstract
PURPOSE: Tumor treating fields (TTF) are alternating electric fields applied continuously to the scalp. The treatment is approved for both primary and recurrent supratentorial adult glioblastoma but unstudied in children. METHODS: We report a feasibility case series of five pediatric high-grade glioma patients (ages 10-20 years) treated at our institution with TTF along with chemotherapy and/or radiation. RESULTS: Two patients began therapy at second recurrence and showed progressive disease. Two others were treated upfront after radiation therapy, and both showed partial responses. A fifth patient was treated at first recurrence and also showed a partial response. All five tolerated TTF well without treatment-limiting toxicities. CONCLUSIONS: The tolerability of TTF, combined with the adult data, justify a pediatric clinical trial.
PURPOSE: Tumor treating fields (TTF) are alternating electric fields applied continuously to the scalp. The treatment is approved for both primary and recurrent supratentorial adult glioblastoma but unstudied in children. METHODS: We report a feasibility case series of five pediatric high-grade gliomapatients (ages 10-20 years) treated at our institution with TTF along with chemotherapy and/or radiation. RESULTS: Two patients began therapy at second recurrence and showed progressive disease. Two others were treated upfront after radiation therapy, and both showed partial responses. A fifth patient was treated at first recurrence and also showed a partial response. All five tolerated TTF well without treatment-limiting toxicities. CONCLUSIONS: The tolerability of TTF, combined with the adult data, justify a pediatric clinical trial.
Entities:
Keywords:
Case series; Glioblastoma; Novocure; Optune
Authors: Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin Journal: Eur J Cancer Date: 2012-05-18 Impact factor: 9.162
Authors: Roger Stupp; Sophie Taillibert; Andrew A Kanner; Santosh Kesari; David M Steinberg; Steven A Toms; Lynne P Taylor; Frank Lieberman; Antonio Silvani; Karen L Fink; Gene H Barnett; Jay-Jiguang Zhu; John W Henson; Herbert H Engelhard; Thomas C Chen; David D Tran; Jan Sroubek; Nam D Tran; Andreas F Hottinger; Joseph Landolfi; Rajiv Desai; Manuela Caroli; Yvonne Kew; Jerome Honnorat; Ahmed Idbaih; Eilon D Kirson; Uri Weinberg; Yoram Palti; Monika E Hegi; Zvi Ram Journal: JAMA Date: 2015-12-15 Impact factor: 56.272
Authors: Gang Wu; Alexander K Diaz; Barbara S Paugh; Sherri L Rankin; Bensheng Ju; Yongjin Li; Xiaoyan Zhu; Chunxu Qu; Xiang Chen; Junyuan Zhang; John Easton; Michael Edmonson; Xiaotu Ma; Charles Lu; Panduka Nagahawatte; Erin Hedlund; Michael Rusch; Stanley Pounds; Tong Lin; Arzu Onar-Thomas; Robert Huether; Richard Kriwacki; Matthew Parker; Pankaj Gupta; Jared Becksfort; Lei Wei; Heather L Mulder; Kristy Boggs; Bhavin Vadodaria; Donald Yergeau; Jake C Russell; Kerri Ochoa; Robert S Fulton; Lucinda L Fulton; Chris Jones; Frederick A Boop; Alberto Broniscer; Cynthia Wetmore; Amar Gajjar; Li Ding; Elaine R Mardis; Richard K Wilson; Michael R Taylor; James R Downing; David W Ellison; Jinghui Zhang; Suzanne J Baker Journal: Nat Genet Date: 2014-04-06 Impact factor: 38.330
Authors: Aleksandrs Krigers; Daniel Pinggera; Matthias Demetz; Lisa-Marie Kornberger; Johannes Kerschbaumer; Claudius Thomé; Christian F Freyschlag Journal: Front Neurol Date: 2022-06-16 Impact factor: 4.086
Authors: Stewart Goldman; Ashley Margol; Eugene I Hwang; Kazuhiro Tanaka; Bogdana Suchorska; John R Crawford; Santosh Kesari Journal: Front Oncol Date: 2022-07-29 Impact factor: 5.738